Search results
A ‘slap in the face’: Retired state workers in Maryland outraged by drug plan switch
Baltimore Sun· 2 days agoInstead, Varner — a professor emeritus at the University of Maryland, College Park, who was...
CVS Health Corporation (NYSE:CVS) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 10 hours agoCVS Health Corporation (NYSE:CVS) Q1 2024 Earnings Call Transcript May 1, 2024 CVS Health...
Care N’ Care Medicare Advantage 2024 Review - NerdWallet
Nerdwallet· 3 days agoCare N' Care Medicare Advantage plans are available in Texas and get below-average star ratings from...
Are you a Medicare, Social Security recipient planning a move? Here's what you should know
The Oklahoman via Yahoo News· 3 days agoIf you tell your plan after you move, your chance to switch plans begins the month you tell your...
CVS Health (CVS) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 1 day agoWe will provide updates throughout the year on these efforts. I also feel it is important to discuss our long-term outlook for Medicare Advantage. We...
Can you Change Your Medicare Plan Outside of Open Enrollment?
TMJ4 Milwaukee· 1 day agoBen DeGracie is back from Sovereign Select to chat about special circumstances for those on Medicare...
CVS stock plunges after earnings numbers one analyst 'did not even believe'
Yahoo Finance via AOL· 1 day agoMargins over membership In order to right-size its balance sheet in the face of more Medicare...
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
Zacks via Yahoo Finance· 9 hours agoSales of Tyvaso DPI were driven by higher volumes and increased commercialization utilization of the...
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 hours agoExelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses...
Wave of Amicus Briefs Back Drug Price Plan at Trial Court Stage
Bloomberg Law· 7 days agoThe Biden administration’s efforts to fend off legal challenges from the pharmaceutical industry battling Medicare drug price negotiations has drawn reinforcements from officials and academics defending the program.